期刊
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
卷 16, 期 18, 页码 4752-4756出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bmcl.2006.06.092
关键词
imidazole; 17 alpha-hydroxylase/17,20-lyase; inhibitors; prostate cancer
We report the preliminary results of the synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a number of phenyl alkyl imidazole-based compounds as inhibitors of the two components of 17 alpha-hydroxylase/17,20-lyase (P450(17 alpha)), that is, 17 alpha-hydroxylase (17 alpha-OHase) and 17,20-lyase (lyase). The results show that N-3-(4-bromophenyl) propyl imidazole (12) (IC50 = 2.95 mu M against 17 alpha-OHase and IC50 = 0.33 mu M against lyase) is the most potent compound within the current study, in comparison to ketoconazole (KTZ) (IC50 = 3.76 mu M against 17 alpha-OHase and IC50 = 1.66 mu M against lyase). Modelling of these compounds suggests that the length of the alkyl chain enhances the interaction between the inhibitor and the area of the active site corresponding to the C(3) area of the steroid backbone, thereby increasing potency. (c) 2006 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据